8-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 25, 2007

MILESTONE SCIENTIFIC INC.

(Exact name of Registrant as specified in its charter)


Delaware	0-26284	13-3545623

(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

220 South Orange Avenue, Livingston Corporate Park, Livingston, New Jersey 07034

(Address of principal executive office) (Zip Code)

Registrant’s telephone number, including area code (973) 535-2717

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.02:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

See our response to Item 8.01 herein.


Item 8.01:		Other Matters.

On June 25, 2007, we issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference, announcing that David Cohn, our current Chief Financial Officer, has indicated his intent to resign from the senior financial post to pursue new career opportunities and consequently, we have initiated a search for a new CFO. Mr. Cohn has agreed to continue serving us until his replacement is hired and will offer his ongoing support through a reasonable transitional period.


Item 9.01:		Financial Statements and Exhibits

(d) Exhibits:

99.1 Press Release dated June 25, 2007.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	MILESTONE SCIENTIFIC INC.
	By:	/s/ Leonard Osser
		Leonard Osser Chairman and Chief Executive Officer

Dated: June 25, 2007

MILESTONE SCIENTIFIC ANNOUNCES PLANS
TO APPOINT NEW CHIEF FINANCIAL OFFICER

Current CFO to Resign to Pursue New Career Opportunities

LIVINGSTON, N.J. — (PR NEWSWIRE) — June 25, 2007 — Milestone Scientific, Inc. (OTCBB:MLSS), the recognized leader in advanced injection technologies, today announced that David Cohn, current Chief Financial Officer of the Company, has indicated his intent to resign from the senior financial post to pursue new career opportunities. Consequently, the Company has initiated a search for a new CFO that it expects to appoint as soon as possible. Cohn has agreed to continue serving Milestone until his replacement is hired and will offer his ongoing support through a reasonable transitional period.

Leonard Osser, Chairman and Chief Executive Officer of Milestone, noted, “We would like to thank Dave for his exceptional leadership over the past year and wish him well in his future endeavors. Milestone has already initiated its search for Dave’s replacement.”

About Milestone Scientific, Inc.
Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company’s IP platform and product development strategy is its patented CompuFlo^™ technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The Single Tooth Anesthesia (STA^™) computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone’s existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company’s web site found at www.milesci.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of the Milestone’s ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report on Form 10-KSB for the year ended December 31, 2006. The forward looking-statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

FOR MORE INFORMATION, PLEASE CONTACT:
Elite Financial Communications Group, LLC
Dodi Handy, President and CEO, or
Daniel Conway, Chief Strategist
407-585-1080 or via email at mlss@efcg.net